Lantern Pharma Stock News

Lantern Pharma Inc.'s (LTRN) CEO Panna Sharma on Q4 2021 Results - Earnings Call Transcript

The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for Atypical Teratoid Rhabdoid Tumor (ATRT), a form of cancer of the Central N

Lantern Pharma Inc (LTRN) shares closed today at 1.2% above its 52 week low of $6.89, giving the company a market cap of $77M. The stock is currently down 12.7% year-to-date, down 63.5% over the past 12 months, and down 53.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 18.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1016.1% The company's stock price performance over the past 12 months lags the peer average by 954.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

DALLAS, Jan. 4, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the

Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q3 2021 Results - Earnings Call Transcript

DALLAS, Oct. 25, 2021 /PRNewswire/ --  Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform

DALLAS, TX / ACCESSWIRE / September 30, 2021 / Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transf

DALLAS and COLUMBUS, Ohio, Sept. 28, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.

DALLAS, Sept. 7, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.

DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.

The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for glioblastoma multiforme (GBM) and other malignant gliomas. The news follows the recent announcement of the

Lantern Pharma Inc (NASDAQ: LTRN) announced preclinical data of its drug candidate LP-184, showing its potential to inhibit tumor growth and improve survival in animals models of glioblastoma (GBM)

DALLAS and BALTIMORE, Aug. 19, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company, announced today that a successful preclinical study has shown its drug

DALLAS, Aug. 16, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the

The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for pancreatic cancer.  LP-184 is a small molecule drug candidate and next-generation alkylating agent th